Peter Hecht’s Ironwood spinout fails back-to-back studies on a key drug, crushing shares and triggering cutbacks — but he still sees a path forward
Peter Hecht’s plan to pivot from a mid-stage start at his newly created biotech Cyclerion — spun out of Ironwood — right into late-stage programs on a path to commercialization has run straight into a major setback.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
